Cellular mechanisms underlying affective resiliency: The role of glucocorticoid receptor- and mitochondrially-mediated plasticity

Brain Research

Volumn 1293, Issue , 2009, Pages 76-84

  Hunsberger, Joshua G ^a   Austin, Daniel R ^a   Chen, Guang ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

BAG 1; Bcl 2; Bipolar disorder; FKBP5; Glucocorticoid receptor; Resiliency

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BAG 1 PROTEIN; FK 506 BINDING PROTEIN; GLUCOCORTICOID RECEPTOR; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; PROTEIN BNIP3; VALPROIC ACID;

APOPTOSIS; BIPOLAR DISORDER; CELLULAR STRESS RESPONSE; DRUG ACTIVITY; DRUG TARGETING; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MITOCHONDRION; NEUROBIOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADAPTATION, PHYSIOLOGICAL; ANTIMANIC AGENTS; APOPTOSIS; BIPOLAR DISORDER; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEURONAL PLASTICITY; PITUITARY-ADRENAL SYSTEM; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 70149104789     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.06.103     Document Type: Review

References (70)

1. Alberti S., Esser C., and Hohfeld J. BAG-1-a nucleotide exchange factor of Hsc70 with multiple cellular functions. Cell Stress Chaperones 8 (2003) 225-231
2. Angrilli A., Palomba D., Cantagallo A., Maietti A., and Stegagno L. Emotional impairment after right orbitofrontal lesion in a patient without cognitive deficits. NeuroReport 10 (1999) 1741-1746
3. Baldessarini R.J., Hennen J., Wilson M., Calabrese J., Chengappa R., Keck Jr. P.E., McElroy S.L., Sachs G., Vieta E., Welge J.A., Yatham L.N., Zarate Jr. C.A., Baker R.W., and Tohen M. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J. Clin. Psychopharmacol. 23 (2003) 370-376
4. Basta-Kaim A., Budziszewska B., Jaworska-Feil L., Tetich M., Kubera M., Leskiewicz M., and Lason W. Mood stabilizers inhibit glucocorticoid receptor function in LMCAT cells. Eur. J. Pharmacol. 495 (2004) 103-110
5. Beyer J.L., and Krishnan K.R. Volumetric brain imaging findings in mood disorders. Bipolar Disord. 4 (2002) 89-104
6. Bian Q., Shi T., Chuang D.M., and Qian Y. Lithium reduces ischemia-induced hippocampal CA1 damage and behavioral deficits in gerbils. Brain Res. 1184 (2007) 270-276
7. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Putz B., Papiol S., Seaman S., Lucae S., Kohli M.A., Nickel T., Kunzel H.E., Fuchs B., Majer M., Pfennig A., Kern N., Brunner J., Modell S., Baghai T., Deiml T., Zill P., Bondy B., Rupprecht R., Messer T., Kohnlein O., Dabitz H., Bruckl T., Muller N., Pfister H., Lieb R., Mueller J.C., Lohmussaar E., Strom T.M., Bettecken T., Meitinger T., Uhr M., Rein T., Holsboer F., and Muller-Myhsok B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36 (2004) 1319-1325
8. Brotman M.A., Guyer A.E., Lawson E.S., Horsey S.E., Rich B.A., Dickstein D.P., Pine D.S., and Leibenluft E. Facial emotion labeling deficits in children and adolescents at risk for bipolar disorder. Am. J. Psychiatry (2008)
9. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., and Manji H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72 (1999) 879-882
10. Drevets W.C. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr. Opin. Neurobiol. 11 (2001) 240-249
11. Drevets W.C., Ongur D., and Price J.L. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. Mol. Psychiatry 3 220-6 (1998) 190-191
12. Drevets W.C., Savitz J., and Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr. 13 (2008) 663-681
13. Du, J., Wang, Y., Hunter, R., Wei, Y., Blumenthal, R., Falke, C., Khairova, R., Zhou, R., Yuan, P., Machado-Vieira, B., McEwen, B., Manji, H.K., in press. Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A.
14. Duman R.S., Malberg J., and Thome J. Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry 46 (1999) 1181-1191
15. Einat H., Yuan P., Gould T.D., Li J., Du J., Zhang L., Manji H.K., and Chen G. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 23 (2003) 7311-7316
16. Einat H., Yuan P., and Manji H.K. Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: further support for the involvement of mitochondrial function in anxiety disorders. Behav. Brain Res. 165 (2005) 172-180
17. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., and Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 158 (2001) 100-106
18. Goodwin F.K., and Jamison K.R. Manic-depressive Illness: Bipolar Disorders and Recurrent Depression (2007), Oxford University Press, Oxford; New York Vol.
19. Grafman J., Vance S.C., Weingartner H., Salazar A.M., and Amin D. The effects of lateralized frontal lesions on mood regulation. Brain 109 Pt. 6 (1986) 1127-1148
20. Hochman A., Liang H., Offen D., Melamed E., and Sternin H. Developmental changes in antioxidant enzymes and oxidative damage in kidneys, liver and brain of bcl-2 knockout mice. Cell. Mol. Biol. (Noisy-le-grand) 46 (2000) 41-52
21. Holsboer F., Lauer C.J., Schreiber W., and Krieg J.C. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 62 (1995) 340-347
22. Institute of Medicine. Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships. Workshop Summary (2008), Institute of Medicine, Washington, DC Vol.
23. Joseph R. Frontal lobe psychopathology: mania, depression, confabulation, catatonia, perseveration, obsessive compulsions, and schizophrenia. Psychiatry 62 (1999) 138-172
24. Kermer P., Krajewska M., Zapata J.M., Takayama S., Mai J., Krajewski S., and Reed J.C. Bag1 is a regulator and marker of neuronal differentiation. Cell Death Differ. 9 (2002) 405-413
25. Kruger S., Alda M., Young L.T., Goldapple K., Parikh S., and Mayberg H.S. Risk and resilience markers in bipolar disorder: brain responses to emotional challenge in bipolar patients and their healthy siblings. Am. J. Psychiatry 163 (2006) 257-264
26. Lai J.S., Zhao C., Warsh J.J., and Li P.P. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur. J. Pharmacol. 539 (2006) 18-26
27. Lee A.L., Ogle W.O., and Sapolsky R.M. Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord. 4 (2002) 117-128
28. Lekman M., Laje G., Charney D., Rush A.J., Wilson A.F., Sorant A.J., Lipsky R., Wisniewski S.R., Manji H., McMahon F.J., and Paddock S. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol. Psychiatry (2008)
29. Maeng S., Hunsberger J.G., Pearson B., Yuan P., Wang Y., Wei Y., McCammon J., Schloesser R.J., Zhou R., Du J., Chen G., McEwen B., Reed J.C., and Manji H.K. BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 8766-8771
30. Magarinos A.M., McEwen B.S., Flugge G., and Fuchs E. Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. J. Neurosci. 16 (1996) 3534-3540
31. Maguire T.M., Thakore J., Dinan T.G., Hopwood S., and Breen K.C. Plasma sialyltransferase levels in psychiatric disorders as a possible indicator of HPA axis function. Biol. Psychiatry 41 (1997) 1131-1136
32. Manji H.K., Moore G.J., and Chen G. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J. Clin. Psychiatry 61 Suppl. 9 (2000) 82-96
33. Manji H.K., Quiroz J.A., Payne J.L., Singh J., Lopes B.P., Viegas J.S., and Zarate C.A. The underlying neurobiology of bipolar disorder. World Psychiatry 2 (2003) 136-146
34. McElroy S.L., Zarate C.A., Cookson J., Suppes T., Huffman R.F., Greene P., and Ascher J. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J. Clin. Psychiatry 65 (2004) 204-210
35. McEwen B.S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 54 (2005) 20-23
36. McQuade R., Leitch M.M., Gartside S.E., and Young A.H. Effect of chronic lithium treatment on glucocorticoid and 5-HT1A receptor messenger RNA in hippocampal and dorsal raphe nucleus regions of the rat brain. J. Psychopharmacol. 18 (2004) 496-501
37. McQuillin A., Rizig M., and Gurling H.M. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet. Genomics 17 (2007) 605-617
38. Miller A.H., Pariante C.M., and Pearce B.D. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv. Exp. Med. Biol. 461 (1999) 107-116
39. Modell S., Lauer C.J., Schreiber W., Huber J., Krieg J.C., and Holsboer F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology 18 (1998) 253-262
40. Moore G.J., Bebchuk J.M., Hasanat K., Chen G., Seraji-Bozorgzad N., Wilds I.B., Faulk M.W., Koch S., Glitz D.A., Jolkovsky L., and Manji H.K. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?. Biol. Psychiatry 48 (2000) 1-8
41. Murray F., and Hutson P.H. Hippocampal Bcl-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT(1A) or 5-HT(2C/2B) receptor antagonists. Eur. J. Pharmacol. 569 (2007) 41-47
42. Oral E.T., and Vahip S. Bipolar depression: an overview. IDrugs 7 (2004) 846-850
43. Pariante C.M., and Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49 (2001) 391-404
44. Post R.M., Leverich G.S., Nolen W.A., Kupka R.W., Altshuler L.L., Frye M.A., Suppes T., McElroy S., Keck P., Grunze H., and Walden J. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord. 5 (2003) 396-406
45. Rajkowska G., Halaris A., and Selemon L.D. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol. Psychiatry 49 (2001) 741-752
46. Reynolds P.D., Ruan Y., Smith D.F., and Scammell J.G. Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. J. Clin. Endocrinol. Metab. 84 (1999) 663-669
47. Rybakowski J.K., and Twardowska K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J. Psychiatr. Res. 33 (1999) 363-370
48. Sajatovic M., Valenstein M., Blow F.C., Ganoczy D., and Ignacio R.V. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 8 (2006) 232-241
49. Sapolsky R.M., Romero L.M., and Munck A.U. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21 (2000) 55-89
50. Schneikert J., Hubner S., Martin E., and Cato A.C. A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of glucocorticoid receptor activity. J. Cell Biol. 146 (1999) 929-940
51. Shaltiel G., Chen G., and Manji H.K. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr. Opin. Pharmacol. 7 (2007) 22-26
52. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., and Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22 (2002) 3251-3261
53. Smoller J.W., and Finn C.T. Family, twin, and adoption studies of bipolar disorder. Am. J. Med. Genet. C Semin. Med. Genet. 123 (2003) 48-58
54. Steller H. Mechanisms and genes of cellular suicide. Science 267 (1995) 1445-1449
55. Strakowski S.M., DelBello M.P., Zimmerman M.E., Getz G.E., Mills N.P., Ret J., Shear P., and Adler C.M. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am. J. Psychiatry 159 (2002) 1841-1847
56. Takayama S., Sato T., Krajewski S., Kochel K., Irie S., Millan J.A., and Reed J.C. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 80 (1995) 279-284
57. Tohen M., Zhang F., Taylor C.C., Burns P., Zarate C., Sanger T., and Tollefson G. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J. Affect. Disord. 65 (2001) 85-93
58. van Rossum E.F., Binder E.B., Majer M., Koper J.W., Ising M., Modell S., Salyakina D., Lamberts S.W., and Holsboer F. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol. Psychiatry 59 (2006) 681-688
59. van West D., Van Den Eede F., Del-Favero J., Souery D., Norrback K.F., Van Duijn C., Sluijs S., Adolfsson R., Mendlewicz J., Deboutte D., Van Broeckhoven C., and Claes S. Glucocorticoid receptor gene-based SNP analysis in patients with recurrent major depression. Neuropsychopharmacology 31 (2006) 620-627
60. Vermeer H., Hendriks-Stegeman B.I., van der Burg B., van Buul-Offers S.C., and Jansen M. Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J. Clin. Endocrinol. Metab. 88 (2003) 277-284
61. Wassef A., Smith E.M., Rose R.M., Gardner R., Nguyen H., and Meyer W.J. Mononuclear leukocyte glucocorticoid receptor binding characteristics and down-regulation in major depression. Psychoneuroendocrinology 15 (1990) 59-68
62. Watson S., Thompson J.M., Ritchie J.C., Nicol Ferrier I., and Young A.H. Neuropsychological impairment in bipolar disorder: the relationship with glucocorticoid receptor function. Bipolar Disord. 8 (2006) 85-90
63. Wei Q., Lu X.Y., Liu L., Schafer G., Shieh K.R., Burke S., Robinson T.E., Watson S.J., Seasholtz A.F., and Akil H. Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11851-11856
64. Wei Q., Hebda-Bauer E.K., Pletsch A., Luo J., Hoversten M.T., Osetek A.J., Evans S.J., Watson S.J., Seasholtz A.F., and Akil H. Overexpressing the glucocorticoid receptor in forebrain causes an aging-like neuroendocrine phenotype and mild cognitive dysfunction. J. Neurosci. 27 (2007) 8836-8844
65. Willour V.L., Chen H., Toolan J., Belmonte P., Cutler D.J., Goes F.S., Zandi P.P., Lee R.S., Mackinnon D.F., Mondimore F.M., Schweizer B., Depaulo Jr. J.R., Gershon E.S., McMahon F.J., and Potash J.B. Family-based association of FKBP5 in bipolar disorder. Mol. Psychiatry (2008)
66. Zarate Jr. C.A., and Tohen M. Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study. J. Clin. Psychiatry 61 (2000) 33-38
67. Zarate Jr. C.A., and Quiroz J.A. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord. 5 (2003) 217-225
68. Zarate Jr. C.A., and Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am. J. Psychiatry 161 (2004) 169-171
69. Zarate Jr. C.A., Tohen M., Narendran R., Tomassini E.C., McDonald J., Sederer M., and Madrid A.R. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J. Clin. Psychiatry 60 (1999) 232-236
70. Zhou R., Gray N.A., Yuan P., Li X., Chen J., Chen G., Damschroder-Williams P., Du J., Zhang L., and Manji H.K. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J. Neurosci. 25 (2005) 4493-4502